Are the odds shifting against pharma in the fight for cheaper treatment for macular degeneration?

Cohen, Deborah

Cohen, Deborah.

BMJ ; 359: j5016, 2017 10 31.

Article in En | MEDLINE | ID: mdl-29089312

Subject(s)

Angiogenesis Inhibitors; Bevacizumab; Medication Therapy Management/economics; Wet Macular Degeneration/drug therapy; Angiogenesis Inhibitors/classification; Angiogenesis Inhibitors/economics; Angiogenesis Inhibitors/therapeutic use; Bevacizumab/economics; Bevacizumab/therapeutic use; Cost Savings/methods; Cost-Benefit Analysis; Humans; Practice Patterns, Physicians'/economics; State Medicine/economics; United Kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Angiogenesis Inhibitors / Medication Therapy Management / Wet Macular Degeneration / Bevacizumab Type of study: Prognostic_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: BMJ Journal subject: MEDICINA Year: 2017 Document type: Article Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google